CytomX Therapeutics-2026_JPM_CTMX_Presentation_Website.pdf

《CytomX Therapeutics-2026_JPM_CTMX_Presentation_Website.pdf》由会员分享，可在线阅读，更多相关《CytomX Therapeutics-2026_JPM_CTMX_Presentation_Website.pdf（32页珍藏版）》请在三个皮匠报告上搜索。

1、1 2026 CytomX Therapeutics,Inc.Dr.Sean McCarthy,CEO and ChairmanJanuary 14,2026 Unmasking Advances in Oncology44thAnnual JP Morgan Healthcare ConferenceForward-Looking Statements2This presentation may contain projections and other forward-looking statements regarding future events,including those re

2、lated to varsetatug masetecan and CX-801.All statements other than statements of historical facts contained in this presentation,including statements regarding our future financial condition,technology platform,development strategy,prospective products,preclinical and clinical pipeline and milestone

3、s,regulatory objectives and likelihood of success,are forward-looking statements.Such statements are predictions only and involve known and unknown risks,uncertainties and other important factors that may cause our actual results,performance or achievements to be materially different from any future

4、 results,performance or achievements expressed or implied by the forward-looking statements.These risks and uncertainties include,among others,the costs,timing and results of preclinical studies and clinical trials,including varsetatug masetecan and CX-801,and other development activities;uncertaint

5、ies inherent in the initiation and enrollment of clinical trials;uncertainties on the availability and timing of data from clinical trials;the risk that initial clinical data,including data for varsetatug masetecan and CX-801,may not reflect later clinical trial results;the unpredictability of the d

6、uration and results of regulatory review;the uncertainty of market acceptance for approved products and innovative therapeutic treatments;competition;the potential not to receive partnership milestone,profit sharing or royalty payments;the possible impairment of or inability to obtain intellectual p